HDM1002
GLP-1 (small molecule) · oral · Huadong Medicine
Summary
- Also known as
- Zhongmei Huadong
- Mechanism
- GLP-1 (small molecule)
- Route
- oral
- Company
- Huadong Medicine
- Highest development stage
- phase 3
- Status (as of data cut)
- Phase 3 HDM1002-301 positive (oral; up to −12.2 % efficacy estimand at 52 weeks); pre-NDA verify
- Next milestone
- NDA in China
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 3 positive phase 3 | Positive phase 3 HDM1002-301 (oral) | Huadong announcement (Sep 2026) |
| T2D | 2 phase 3 ongoing | Phase 3 registered on ClinicalTrials.gov | |
| CV outcomes | 0 no data | ||
| CKD | 0 no data | ||
| HFpEF | 0 no data | ||
| MASH | 0 no data | ||
| Sleep apnoea | 0 no data | ||
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HDM1002-301 | 200 mg QD | obesity china | 52 | 857 | −10.7 % vs −1.5 % Δ −9.2 pp | −9.4 % vs −1.5 % Δ −7.9 pp | — | 1.5 vs 0.6 | — | — | — | — | — | press release |
| HDM1002-301 | 400 mg QD | obesity china | 52 | 857 | −12.2 % vs −1.5 % Δ −10.7 pp | −11.3 % vs −1.5 % Δ −9.8 pp | — | 2.0 vs 0.6 | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (6)
- 200 mg QD · weight_eff · HKEX filing
第 52 周 -10.7% -12.2% -1.2%
- 200 mg QD · weight_tp · HKEX filing
第 52 周 -9.4% -11.3% -0.9%
- 200 mg QD · ae_dc · 四、安全性 paragraph
因 AE 导致的治疗终止率分别为 1.5% (HDM1002 片 200mg 组)、2.0%(HDM1002 片 400mg 组)和 0.6% (安慰剂组)
- 400 mg QD · weight_eff · HKEX filing
第 52 周 -10.7% -12.2% -1.2%
- 400 mg QD · weight_tp · HKEX filing
第 52 周 -9.4% -11.3% -0.9%
- 400 mg QD · ae_dc · 四、安全性 paragraph
因 AE 导致的治疗终止率分别为 1.5% (HDM1002 片 200mg 组)、2.0%(HDM1002 片 400mg 组)和 0.6% (安慰剂组)
Registered trials (3)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| NCT07193459 Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus | T2D | Phase 3 | recruiting | 2025-08 → 2026-10 | 360 | recruiting | NCT07193459 |
| NCT07082114 A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus | T2D | Phase 3 | recruiting | 2025-07 → 2027-02 | 800 | recruiting | NCT07082114 |
| NCT06885021 · China Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults | Obesity | Phase 3 | not yet recruiting | 2025-03 → 2026-05 | 780 | not yet recruiting | NCT06885021 |
Primary sources
How to cite this page
Cite the primary publication for any single result; every value above links to it.